Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan Cilexetil + Chlorthalidone (16mg + 12.5mg and 16mg + 25mg) Compared With HYZAAR® in Hypertension Control

NCT02521246 Phase 3 WITHDRAWN

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

Details

Lead sponsor	EMS
Phase	Phase 3
Status	WITHDRAWN
Start date	2016-11
Completion	2017-08

Conditions

• Essential Arterial Hypertension

Interventions

• Candesartan + Chlorthalidone
• Candesartan + Chlorthalidone
• Losartan+hydrochlorothiazide

Primary outcomes

• Efficacy of essential hypertension control based on proportion of participants who achieve the therapeutic goal — 60 days